Summary We examined loss of heterozygosity (LOH) for two loci on chromosome 17p (D17S5 and TP53), and erbB-2 gene amplification, in primary breast cancers from 67 Brazilian patients. We identified two distinct regions of LOH on chromosome 17p, one spanning TP53 and the other a more telomeric region (D17S5). Based on a short-term follow-up, Kaplan-Meier analyses of patients' disease-free survival showed that patients with LOH for D17S5, but retaining heterozygosity for TP53, were at higher risk of recurrence (P = 0.007) than those who retained heterozygosity for D17S5. Bivariate analyses indicated that patients with LOH for D17S5 alone had an increased risk of recurrence (hazard ratio = 7.2) over patients with erbB-2 amplification (hazard ratio = 3.7), when compared with patients with neither alteration (hazard ratio = 1.0). Further, lymph node-positive patients whose tumours had both LOH for D17S5 and erbB-2 gene amplification had a higher risk of recurrence than patients whose tumours had neither of these genetic alterations. Our data confirm previous reports of a putative tumour-suppressor gene, distinct from TP53, on distal chromosome 17p which is associated with breast cancer. They further suggest that LOH for loci in this region may provide an independent indicator to identify patients with poor prognosis.
Several tumour-suppressor genes that may contribute to breast cancer tumorigenesis are located on chromosome 17, including NM23 (Leone et al., 1991) , the BRCAJ gene (17ql2-q23) (Hall et al., 1990; Easton et al., 1993) , the TP53 gene (17pl3.1) and at least two other putative tumoursuppressor genes not yet defined (Coles et al., 1990; Sato et al., 1990; Anderson et al., 1992; Jacobs et al., 1993) .
Loss of heterozygosity for loci on chromosome 17p has been reported in 40-60% of sporadic breast carcinomas (Mackay et al., 1988; Cropp et al., 1990; Devilee et al., 1991; Andersen et al., 1992) . Frequently, these genetic alterations include the tumour-suppressor gene TP53. Mutations of this gene have been identified in 20-40% of sporadic primary breast tumours (Coles et al., 1992; Mazars et al., 1992) as well as in the germline of some patients with Li-Fraumeni syndrome, an inherited cancer syndrome associated with breast cancer (Malkin et al., 1990) . However, the frequency of TP53 point mutations in breast tumours is significantly less than the frequency of LOH detected for loci on distal chromosome 17p (Chen et al., 1991; Mazars et al., 1992) . Further, Coles et al. (1990) have demonstrated two independent regions of allelic loss on chromosome 17p in breast tumours, one spanning TP53 and the other involving a more telomeric region, implying the existence of another tumoursuppressor gene distal to TP53.
Previous studies correlating chromosome 17p LOH with clinicopathological variables in breast cancer have generally failed to distinguish between events at TP53 and at the more distal locus (B0rrensen et al., 1990; Cropp et al., 1991; Varley et al., 1991) . There have been two reports of an association between LOH in the telomeric region of chromosome 17p, but not at TP53, and lymph node status (Andersen et al., 1992; Takita et al., 1992) . However, neither of these reports correlated LOH for distal chromosome 17p with overall survival or disease-free survival.
In this study, we analysed a panel of unselected, primary breast tumours from Brazilian patients for LOH at loci on chromosome 17p and for amplification of the erbB-2 oncogene. These parameters were then evaluated singly and in combination as prognostic indicators for breast carcinoma. Oestrogen and progesterone receptor content were determined by charcoal-dextran methods as described previously (Brentani et al., 1981) .
Materials and methods

Tissue
DNA extraction
Tissue were pulverised to a fine powder using a Frozen Tissue Pulverizer (Termovac), resuspended in lysis buffer (10 mM Tris-HCl pH 7.6 1 mM EDTA and 0.6% SDS) containing proteinase K (100 jig ml-') and incubated at 37°C overnight. High molecular weight DNA was extracted with phenol-chloroform and precipitated with ethanol containing 0.3 M sodium acetate.
Southern and dot-blot analyses DNAs from normal and tumour tissue (10 ,ug) were digested with TaqI for 6-12 h at 65°C according to the manufacturer's specifications (Pharmacia, NJ, USA). Digested DNA samples were separated by electrophoresis on 0.8% agarose gels and transferred to nylon membranes.
For dot-blot analysis, dilutions containing 10.0-0.3125 fig of DNA from each sample were alkali denatured and applied to Hybond N filters using a dot-blot apparatus (Gibco-BRL).
Chromosome 17 probes YNZ22.1 (D17S5) (Nakamura et al., 1988) and the 1.6 kb EcoRI fragment of erbB-2 cDNA were labelled by random oligonucleotide priming (Feinberg & Vogelstein, 1983) .
Southern and dot blots were hybridised as previously described (Mulligan et al., 1990) . After autoradiography dotblot filters were stripped of probe and rehybridised using a ,-actin probe.
The intensity of the hybridisation signal was determined by quantitative densitometry using a Joyce Loebl Chromoscan 3. The degree of erbB-2 amplification was determined by comparing tumour and normal densitometric scans. A tumour was considered positive for erbB-2 amplification if it had a 3-fold greater signal intensity than the normal tissue. Tumours were classified as having 3-to 5-fold or >5-fold amplification. Hybridisation with a P-actin probe was used tQ correct for differences in DNA loading.
Polymerase chain reaction (PCR) analysis of microsatellites LOH for TP53 was analysed by PCR using primers for microsatellite polymorphisms (Futreal et al., 1991) . PCR reactions were performed in 25 pl volumes using 50 ng of genomic DNA as described by Futreal et al. (1991) . The products were diluted 1:2 in 90% formamide, 10 mM EDTA, 0.3% bromophenol blue, 0.3% xylene cyanol, boiled for 5 min and resolved on a 6% denaturing polyacrylamide gel. Alleles were detected by autoradiography of dried gels using Kodak X-Omat XAR film for 4-48 h at -70°C.
Statistical methods
Analyses of statistical significance between the genetic events examined and the clinicopathological characteristics of the patients were performed by the chi-square test. For these analyses, patients were divided into categories for the clinicopathological characteristics based on the following points: age < 50 years or > 50 years; tumour size <4 cm or > 4 cm; tumours that were oestrogen receptor negative (< 10 fmol mg-' protein) or positive (>10 fmol mg-' protein); tumours that were progesterone receptor negative (< 20 fmol mg-' protein) or positive (>20 fmol mg' protein); patients lymph node negative or positive; and earlystage tumours (stages I or II) or advanced-stage tumours (stages III or IV).
Two statistical methods were used to assess the prognostic significance of LOH for D17S5 and TP53 in the group of patients analysed. Short-term follow-up disease-free survival curves were calculated based on the Kaplan-Meier product limit technique (Kaplan & Meier, 1958) . Hazard ratios were calculated using the proportional hazard model as described by Cox (1972) . Regression analyses were performed with microcomputer programs as previously described (Marques et al., 1990) .
Results
Sixty-seven paired normal and breast tumour samples were examined for LOH at loci on the short arm of chromosome Twenty-seven patients were constitutively heterozygous for both D17S5 and TP53. These patients were divided into four groups based on whether they lost alleles at D17S5, TP53, neither or both loci (Figure 1) . By comparing the allele loss patterns in these groups we were able to define two distinct regions of allele loss on chromosome 17p, one spanning TP53 and the other a more telomeric region.
To assess the significance of allele losses on chromosome 17p in the development of primary breast cancer, we compared the clinicopathological characteristics (age, tumour size, steroid hormone receptors, lymph node status, clinical stage) of the patients with LOH for either D17S5 alone (group 3) or TP53 alone (group 2) with those of patients who were informative but showed no LOH at either locus. No significant associations were found for D17S5 (Table I) . As group 2 contained only three patients, a similar comparison was not performed.
A Kaplan-Meier analysis of disease-free survival showed that patients whose tumours had LOH for D17S5 alone (group 3) had a significantly shorter (P = 0.007) disease-free interval than patients who were informative but had no LOH at this locus (groups 2 and 4) (Figure 2 ).
Since group 2 contained only three patients, it was not possible to evaluate the prognostic value of TP53 allelic losses alone in these patients. Kaplan-Meier analysis of disease-free survival showed that patients in group 1 also had a shortened disease-free interval, similar to that of patients with LOH for D17S5 alone. This effect might have been due to losses at TP53 or at the more distal tumour-suppressor gene locus. erbB-2 gene amplification was examined in the 42 cases informative for D17S5. Fifteen cases (36%) had amplification of erbB-2 sequences. Representative examples of tumours with erbB-2 gene amplification are shown in Figure 3 . The amplification was 3-to 5-fold in 11 cases and >5-fold in four cases.
To assess the relative utility of LOH at D17S5 and erbB-2 amplification as prognostic indicators, we analysed diseasefree interval with respect to these genetic events. Kaplan-Meier analysis showed that patients with LOH for D17S5 had a poor prognosis irrespective of erbB-2 gene amplification (P = 0.04). Patients with both LOH for D17S5 and erbB-2 amplification had the worst prognosis (P = 0.01) (Figure 4) .
A combined analysis of the effect of LOH at D17S5 and amplification at erbB-2 (Table II) showed that either event increased the risk of recurrence, and the risk was the greastest for patients whose tumours had undergone both events (hazard ratio = 7.2). This effect was increased in patients whose lymph nodes were positive (hazard ratio = 13.2).
Discussion
Our data are consistent with previous reports of two distinct regions of allele loss on chromosome 17p, one encompassing TP53 and the other more distal. In accordance with previous reports on sporadic breast cancer, the frequency of LOH observed for the telomeric region of chromosome 17p was higher than that observed for TP53 (Coles et al., 1990; Sato I Andersen et al., 1992) . Recent studies in breast cancer (Cropp et al., 1990; Andersen et al., 1992) and in astrocytomas (Saxena et al., 1992) (Cropp et al., 1990; Andersen et al., 1992 Bivariate analysis of these data suggests that LOH at D17S5 is a useful prognostic indicator in breast cancer, independent of lymph node involvement. Up to one-third of patients with lymph node-negative breast cancer without adjuvant treatment relapse within 10 years (Early Breast Cancer Trialists' Collaborative Group, 1992) . Thus the identification of prognostic factors, independent of the lymph node status, which can predict the course of the disease is one of the most important goals in breast cancer research. Our results suggest that LOH at loci in the telomeric region of chromosome 17p might be one such independent factor. This is consistent with studies showing an association between LOH at D17S5 and high proliferative index in breast tumours (Chen et al., 1991; Merlo et al., 1992) .
We found no association between the occurrence of LOH for D17S5 and erbB-2 gene amplification. This is consistent with some reports (B0rrensen et al., 1990; Varley et al., 1991) , but not others (Sato et al., 1991; Knyazev et al., 1993) . Bivariate analyses suggested that LOH for DI 7S5 and erbB-2 amplification are each independently associated with a poor prognosis (Table II) . Further, a combination of these two genetic events and lymph node involvement provides an even stronger indication of patient prognosis. Patients with LOH for D17S5 alone or with LOH for D17SS (but not TP53) and with erbB-2 amplification had a 7-fold increased risk of recurrence over patients negative for these genetic events. The risk of recurrence was increased 13-fold for lymph nodepositive patients with both genetic alterations over lymph node-positive patients without these genetic changes. These data suggest that the use of nodal status combined with the analyses of genetic alterations might identify a group of patients with more aggressive disease.
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